Reviewing Artivion (AORT) & Its Competitors

Artivion (NYSE:AORT – Get Free Report) is one of 510 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare Artivion to related businesses based on the strength of its dividends, institutional ownership, earnings, risk, analyst recommendations, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Artivion and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artivion 1 0 6 0 2.71
Artivion Competitors 4330 10559 18358 840 2.46

Artivion currently has a consensus price target of $39.00, suggesting a potential upside of 114.29%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.64%. Given Artivion’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Artivion is more favorable than its peers.

Profitability

This table compares Artivion and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Artivion -3.65% 5.12% 2.36%
Artivion Competitors -191.42% -197.86% -21.83%

Valuation & Earnings

This table compares Artivion and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Artivion $481.88 million $9.77 million -50.56
Artivion Competitors $1.90 billion $136.32 million 5.94

Artivion’s peers have higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

86.4% of Artivion shares are owned by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Artivion has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Artivion’s peers have a beta of 2.53, meaning that their average share price is 153% more volatile than the S&P 500.

Summary

Artivion beats its peers on 7 of the 13 factors compared.

About Artivion

(Get Free Report)

Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.